ATXN7L1 Inhibitors
ATXN7L1, a protein encoded by the ATXN7L1 gene, plays a crucial role in cellular processes such as transcription regulation and chromatin remodeling. The inhibitors targeting this protein work by disrupting the protein's normal function within these specific cellular pathways. For example, an inhibitor might bind directly to the ATXN7L1 protein, altering its conformation, and thereby preventing it from interacting with other proteins or DNA sequences it typically regulates. Alternatively, some inhibitors may function by interfering with the post-translational modifications of ATXN7L1, which are necessary for its activity. These modifications often involve the addition or removal of specific molecular groups that are essential for the proper localization, stability, or interaction of the protein with other cellular components. In this way, ATXN7L1 inhibitors can effectively reduce the protein's regulatory influence within the cell, leading to a decrease in the transcriptional activity of genes that are normally under its control.
The inhibitors of ATXN7L1 are diverse in structure and mode of action, yet they all converge on the common goal of impeding ATXN7L1's role in the cell. Some of these inhibitors might mimic the substrate or product of the reaction catalyzed by ATXN7L1, acting as competitive antagonists. Others could be allosteric inhibitors that bind to a site on the protein distinct from the active site, inducing a structural change that diminishes its activity. There are also inhibitors that might block the interaction between ATXN7L1 and other proteins in multi-protein complexes, thus disrupting the functional assemblies that are necessary for ATXN7L1's role in gene expression. By manipulating the intricate web of interactions in which ATXN7L1 is involved, these inhibitors can impede the cascades of events that lead to the execution of its biological functions. The precision with which these inhibitors affect ATXN7L1 is a testament to the nuanced understanding of the protein's role in cellular pathways and underscores the complexity of developing targeted inhibitors that can selectively interfere with a single protein's function without causing widespread disruption to numerous cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that can potentially reduce ATXN7L1 activity by preventing phosphorylation events that are necessary for ATXN7L1 function within the cell cycle regulation. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $60.00 $150.00 $226.00 $495.00 | 1 | |
Kenpaullone, another inhibitor of cyclin-dependent kinases, may lead to decreased ATXN7L1 activity by a similar mechanism as alsterpaullone, impacting cell cycle progression and thus indirectly affecting ATXN7L1's role in transcriptional regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is a selective inhibitor of cyclin-dependent kinases. By inhibiting these kinases, it may lead to reduced phosphorylation and activation of proteins that interact with ATXN7L1, thereby diminishing ATXN7L1's functional activity in gene expression control. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime is a potent inhibitor of cyclin-dependent kinases and GSK-3β. It could diminish ATXN7L1 activity by altering the phosphorylation state of proteins within the pathways where ATXN7L1 is implicated, particularly in transcriptional regulation and chromatin remodeling. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits several cyclin-dependent kinases that are crucial for cell cycle progression. This inhibition may decrease the functional activity of ATXN7L1 by modulating the proteins that regulate transcription and chromatin structure, where ATXN7L1 has known roles. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of Jun N-terminal kinase (JNK), which can indirectly reduce ATXN7L1 activity by influencing transcription factors and co-regulators that interact with ATXN7L1 in cellular stress response pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which indirectly affects ATXN7L1 by potentially altering the phosphorylation state of transcription factors and histones that ATXN7L1 associates with, thereby influencing its involvement in gene expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could potentially reduce ATXN7L1 activity by affecting the transcriptional machinery and signaling pathways where ATXN7L1 is a component, especially in response to inflammatory stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that may lead to decreased ATXN7L1 activity by impacting the AKT signaling pathway and thus influencing transcription factors and chromatin remodeling complexes associated with ATXN7L1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that could decrease ATXN7L1 activity by a similar mechanism to LY294002, potentially affecting the protein's role in transcriptional regulation. | ||||||